Cantargia reports filing of opposition against Cantargia patent in Europe

Booking.com

Cantargia AB today announces that an opposition has been filed against one of the European patents in Cantargia’s patent family covering antibody therapy in solid tumors. The patent, with number EP3020730B1, confers protection for e.g. IL1RAP targeted antibodies in tumor forms not already covered in the European mother patent, which was granted in 2016. The current opponent, Mab Discovery GmbH, also filed an opposition against the mother patent in 2016. That opposition was unsuccessful and the mother patent, valid until 2032, remains in force after the opposition proceedings were concluded in

Source: Cantargia reports filing of opposition against Cantargia patent in Europe

Booking.com
Booking.com

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.